Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia.
Aged
Aged, 80 and over
Azabicyclo Compounds
/ administration & dosage
Double-Blind Method
Female
Humans
Hypnotics and Sedatives
/ administration & dosage
Male
Melatonin
/ administration & dosage
Middle Aged
Piperazines
/ administration & dosage
Quality of Life
Sleep
/ drug effects
Sleep Aids, Pharmaceutical
/ administration & dosage
Sleep Initiation and Maintenance Disorders
/ drug therapy
Substance Withdrawal Syndrome
/ psychology
Surveys and Questionnaires
Temazepam
/ administration & dosage
Zolpidem
/ administration & dosage
Z-drugs
benzodiazepine agonists
older outpatients
perceived sleep
primary insomnia
quality of life
withdrawal from chronic use
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
21
06
2018
accepted:
24
09
2018
pubmed:
9
10
2018
medline:
6
7
2019
entrez:
9
10
2018
Statut:
ppublish
Résumé
Long-term use of benzodiazepines or benzodiazepine receptor agonists is widespread, although guidelines recommend short-term use. Only few controlled studies have characterized the effect of discontinuation of their chronic use on sleep and quality of life. We studied perceived sleep and quality of life in 92 older (age 55-91 years) outpatients with primary insomnia before and after withdrawal from long-term use of zopiclone, zolpidem or temazepam (BZDA). BZDA was withdrawn during 1 month, during which the participants received psychosocial support and blindly melatonin or placebo. A questionnaire was used to study perceived sleep and quality of life before withdrawal, and 1 month and 6 months later. 89 participants completed the 6-month follow-up. As melatonin did not improve withdrawal, all participants were pooled and then separated based solely on the withdrawal results at 6 months (34 Withdrawers. 55 Nonwithdrawers) for this secondary analysis. At 6 months, the Withdrawers had significantly (P < 0.05) shorter sleep-onset latency and less difficulty in initiating sleep than at baseline and when compared to Nonwithdrawers. Compared to baseline, both Withdrawers and Nonwithdrawers had at 6 months significantly (P < 0.05) less fatigue during the morning and daytime. Stress was alleviated more in Withdrawers than in Nonwithdrawers (P < 0.05). Satisfaction with life and expected health 1 year later improved (P < 0.05) in Withdrawers. In conclusion, sleep disturbances, daytime fatigue and impaired quality of life may resolve within 6 months of BZDA withdrawal. These results encourage withdrawal from chronic use of benzodiazepine-type hypnotics, particularly in older subjects.
Substances chimiques
Azabicyclo Compounds
0
Hypnotics and Sedatives
0
Piperazines
0
Sleep Aids, Pharmaceutical
0
zopiclone
03A5ORL08Q
Zolpidem
7K383OQI23
Temazepam
CHB1QD2QSS
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-340Subventions
Organisme : Finnish Cultural Foundation
Organisme : Satakunta Hospital District Grant EVO
Organisme : Southwest Finland Hospital District Grant EVO
Organisme : Härkätie Grant EVO
Informations de copyright
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).